Glenn Heller
YOU?
Author Swipe
View article: Stage 0+ lower gastrointestinal (LGI) acute graft-versus-host disease (aGVHD) is associated with high response to non-systemic treatment, low incidence of moderate to severe chronic graft-versus-host disease (cGVHD) and low non-relapse mortality (NRM)
Stage 0+ lower gastrointestinal (LGI) acute graft-versus-host disease (aGVHD) is associated with high response to non-systemic treatment, low incidence of moderate to severe chronic graft-versus-host disease (cGVHD) and low non-relapse mortality (NRM) Open
Introduction: LGI aGVHD remains a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (alloHCT). Stage 0+ LGI aGVHD, defined as low-volume diarrhea (1–499 mL/day or 1–2 episodes/day), is recognized in…
View article: Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases
Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases Open
View article: POS1399 THE AVAILABILITY OF SERINE IS CRITICAL FOR OSTEOCLAST DIFFERENTIATION
POS1399 THE AVAILABILITY OF SERINE IS CRITICAL FOR OSTEOCLAST DIFFERENTIATION Open
View article: Supplementary Tables 1 from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
Supplementary Tables 1 from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201) Open
Supplementary Tables
View article: Supplementary Figure 1 from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
Supplementary Figure 1 from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201) Open
Supplementary Figure 1
View article: Data from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
Data from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201) Open
Purpose:Mutations in hematopoietic progenitor cells accumulate with age leading to clonal expansion, termed clonal hematopoiesis (CH). CH in the general population is associated with hematopoietic neoplasms and reduced overall survival (OS…
View article: Supplementary Data 1 from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
Supplementary Data 1 from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201) Open
Supplementary Data
View article: Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201) Open
Purpose: Mutations in hematopoietic progenitor cells accumulate with age leading to clonal expansion, termed clonal hematopoiesis (CH). CH in the general population is associated with hematopoietic neoplasms and reduced overall survival (O…
View article: Supplementary Table 2 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Supplementary Table 2 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer Open
Pharmacokinetics Data
View article: Measuring the impact of new risk factors within survival models
Measuring the impact of new risk factors within survival models Open
Survival is poor for patients with metastatic cancer, and it is vital to examine new biomarkers that can improve patient prognostication and identify those who would benefit from more aggressive therapy. In metastatic prostate cancer, 2 ne…
View article: Supplementary Table 1 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Supplementary Table 1 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer Open
Dose reductions
View article: Supplementary Table 4 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Supplementary Table 4 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer Open
Patient Representativeness
View article: Supplementary Figure 1 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Supplementary Figure 1 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer Open
Pharmacokinetics
View article: Supplementary Table 2 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Supplementary Table 2 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer Open
Pharmacokinetics Data
View article: Supplemental Table 3 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Supplemental Table 3 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer Open
Immunohistochemistry results
View article: Supplementary Figure 1 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Supplementary Figure 1 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer Open
Pharmacokinetics
View article: Supplemental Table 3 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Supplemental Table 3 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer Open
Immunohistochemistry results
View article: Supplementary Table 1 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Supplementary Table 1 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer Open
Dose reductions
View article: Supplementary Table 4 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Supplementary Table 4 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer Open
Patient Representativeness
View article: Data from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Data from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer Open
Purpose:Recurrent small-cell lung cancer (SCLC) has few effective treatments. The EZH2-SLFN11 pathway is a driver of acquired chemoresistance that may be targeted.Patients and Methods:This phase I/II trial investigated valemetostat, an EZH…
View article: Data from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Data from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer Open
Purpose:Recurrent small-cell lung cancer (SCLC) has few effective treatments. The EZH2-SLFN11 pathway is a driver of acquired chemoresistance that may be targeted.Patients and Methods:This phase I/II trial investigated valemetostat, an EZH…
View article: Measuring the Impact of New Risk Factors Within Survival Models
Measuring the Impact of New Risk Factors Within Survival Models Open
Survival is poor for patients with metastatic cancer, and it is vital to examine new biomarkers that can improve patient prognostication and identify those who would benefit from more aggressive therapy. In metastatic prostate cancer, two …
View article: A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer Open
Purpose: Recurrent small-cell lung cancer (SCLC) has few effective treatments. The EZH2-SLFN11 pathway is a driver of acquired chemoresistance that may be targeted. Patients and Methods: This phase I/II trial investigated valemetostat, an …
View article: SurvEval: Methods for the Evaluation of Survival Models
SurvEval: Methods for the Evaluation of Survival Models Open
Provides predictive accuracy tools to evaluate time-to-event survival models.This includes calculating the concordance probability estimate that incorporates the followup time for a particular study developed by Devlin, Gonen, Heller (2020…
View article: Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors
Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors Open
View article: Prehabilitation and Supportive Care in Oncology Treatment for women with Breast Cancer (PROactive-B) receiving neoadjuvant chemotherapy: program development and feasibility
Prehabilitation and Supportive Care in Oncology Treatment for women with Breast Cancer (PROactive-B) receiving neoadjuvant chemotherapy: program development and feasibility Open
Background: Women treated for breast cancer typically experience an intensive treatment phase including surgery, systemic therapy and radiation therapy. The increased use of neoadjuvant therapy in early stage, but high-risk breast cancer, …
View article: Author Correction: T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection
Author Correction: T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection Open
View article: Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report Open
View article: Supplementary Figure from Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation
Supplementary Figure from Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation Open
Supplementary Figure from Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation
View article: Supplemental Figure 2 from Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade
Supplemental Figure 2 from Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade Open
Inhibition of JAK1/2 with ruxolitinib reduces NK cell numbers and function among treated patients with myeloproliferative neoplasm (MPN).